Skip to main content
. 2017 Mar 21;23(11):1954–1963. doi: 10.3748/wjg.v23.i11.1954

Table 3.

Risk factors for novel oral anticoagulant-related gastrointestinal bleeding

Risk factors Definition
Higher dose of dabigatran and edoxaban Dabigatran: a dose of 150 mg b.i.d
Edoxaban: a dose of 60 mg daily
Concomitant use of ulcerogenic agents Antiplatelet agents, NSAIDs or steroid
Older age Age ≥ 75 years
Renal impairment Creatinine clearance < 50 mL/min
Prior history of peptic ulcers or GIB
Helicobacter pylori infection
Pre-existing GI tract lesions Examples like diverticulosis, angiodysplasias
Ethnicity Western population
HAS-BLED score Score of ≥ 3
Protective factors Definition
Gastroprotective agents Proton pump inhibitors or histamine H2-receptor antagonists

NOAC: Novel oral anticoagulant; GIB: Gastrointestinal bleeding; NSAIDs: Non-steroidal anti-inflammatory drugs.